ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

ClinicalTrials.gov ID: NCT00853658

Public ClinicalTrials.gov record NCT00853658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

Study identification

NCT ID
NCT00853658
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
7,064 participants

Conditions and interventions

Interventions

  • Aliskiren Drug
  • Enalapril Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2009
Primary completion
Sep 30, 2015
Completion
Sep 30, 2015
Last update posted
Nov 24, 2016

2009 – 2015

United States locations

U.S. sites
58
U.S. states
22
U.S. cities
54
Facility City State ZIP Site status
Novartis Investigative Site Huntsville Alabama 35801
Novartis Investigative Site Mobile Alabama 36608
Novartis Investigative Site Mobile Alabama 36693
Novartis Investigative Site Tucson Arizona 85723-0001
Novartis Investigative Site Hot Springs Arkansas 71913
Novartis Investigative Site Little Rock Arkansas 72204
Novartis Investigative Site Little Rock Arkansas 72205
Novartis Investigative Site Pine Bluff Arkansas 71603
Novartis Investigative Site Searcy Arkansas 72143
Novartis Investigative Site Beverly Hills California 90211
Novartis Investigative Site French Camp California 95231
Novartis Investigative Site Inglewood California 90301
Novartis Investigative Site Los Angeles California 90073
Novartis Investigative Site Modesto California 95355
Novartis Investigative Site Northridge California 91325
Novartis Investigative Site Sacramento California 95825
Novartis Investigative Site San Diego California 92123
Novartis Investigative Site Santa Monica California 90404
Novartis Investigative Site Westlake Village California 91361
Novartis Investigative Site Denver Colorado 80218
Novartis Investigative Site Littleton Colorado 80120
Novartis Investigative Site Boynton Beach Florida 33437
Novartis Investigative Site Daytona Beach Florida 32117
Novartis Investigative Site Fort Lauderdale Florida 33316
Novartis Investigative Site Hollywood Florida 33021
Novartis Investigative Site Jacksonville Beach Florida 32050
Novartis Investigative Site Miami Lakes Florida 33014
Novartis Investigative Site Orlando Florida 32803
Novartis Investigative Site Wellington Florida 33449
Novartis Investigative Site Athens Georgia 30606
Novartis Investigative Site Augusta Georgia 30904
Novartis Investigative Site Gillespie Illinois 62033
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Metairie Louisiana 70006
Novartis Investigative Site New Orleans Louisiana 70121
Novartis Investigative Site Slidell Louisiana 70458
Novartis Investigative Site Auburn Maine 04210
Novartis Investigative Site Southfield Michigan 48075
Novartis Investigative Site St Louis Missouri 63110
Novartis Investigative Site Lincoln Nebraska 68506
Novartis Investigative Site Omaha Nebraska 68198
Novartis Investigative Site Elmer New Jersey 08318
Novartis Investigative Site Laurelton New York 11422
Novartis Investigative Site Stony Brook New York 11794
Novartis Investigative Site Wiliamsville New York 14221
Novartis Investigative Site Durham North Carolina 27710
Novartis Investigative Site Marion Ohio 43302
Novartis Investigative Site Charleston South Carolina 29403
Novartis Investigative Site Varnville South Carolina 29944
Novartis Investigative Site Germantown Tennessee 38138
Novartis Investigative Site Memphis Tennessee 38120
Novartis Investigative Site Nashville Tennessee 37205
Novartis Investigative Site Nashville Tennessee 37212
Novartis Investigative Site Dallas Texas 75226
Novartis Investigative Site Houston Texas 77021
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site Everett Washington 98208
Novartis Investigative Site Kirkland Washington 98034

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 748 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00853658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2016 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00853658 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →